EVALUATION OF ANTHELMINTIC AND ANTIOXIDANT ACTIVITIES OF EPIPRINUS MALLOTIFORMIS LEAF EXTRACTS

Objective: Development of anthelmintic resistance and high cost of conventional anthelmintic drugs led to the evaluation of medicinal plants as an alternative source of anthelmintics. The aim of the present study was to investigate the anthelmintic activity and antioxidant activity of the leaves of Epiprinus mallotiformis extract using adult earthworm, Pheritima posthuma. Methods: The leaves extracts of Epiprinus mallotiformis at different concentrations of 20 mg/mL, 40 mg/mL, 60 mg/mL, 80 mg/mL and 100 mg/mL were tested, which involve determination of paralysis time and death time. Results: It was found that the extract exhibited significant dose dependent anthelmintic activity. Piperazine citrate 10 mg/ml as standard reference. Whereas antioxidant activity of the extracts were performed by four method, DPPH  free radical scavenging activity, H2O2 scavenging activity, Reducing power assay and Metal chelating activity using ascorbic acid as a standard. The antioxidant activity was found more in the methanol extracts show comparable activity with ascorbic acid. In the metal chelating activity the petroleum ether show maximum activity when compare with chloroform and methanol. Conclusion: The leaves extracts of Epiprinus mallotiformis possess antioxidant and anthelminthic property. Further investigations on in vivo antioxidant activity need to be carried out to unmask its mode of action. Keywords: Epiprinus mallotiformis; anthelmintic; antioxidant; leaf extracts

Synthesis, optimization and applications of ZnO/polymer nanocomposites

Polymer composites have established an excellent position among the technologically essential materials because of their wide range of applications. An enormous research interest has been devoted to zinc oxide (ZnO) based polymer nanocomposites, due to their exceptional electrical, optical, thermal, mechanical, catalytic, and biomedical properties. This article provides a review of various polymer composites consisting of ZnO nanoparticles (NPs) as reinforcements, exhibiting excellent properties for applications such as the dielectric, sensing, piezoelectric, electromagnetic shielding, thermal conductivity and energy storage. The preparation methods of such composites including solution blending, in situ polymerization, and melt intercalation are also explained. The current challenges and potential applications of these composites are provided in order to guide future progress on the development of more promising materials. Finally, a detailed summary of the current trends in the field is presented to progressively show the future prospects for the development of ZnO containing polymer nanocomposite materials.This publication was made possible by the support of an NPRP grant from the Qatar National Research Fund (NPRP 7- 673- 2- 251 ).Scopu

The Changing Landscape for Stroke Prevention in AF Findings From the GLORIA-AF Registry Phase 2

Thrombosis and Hemostasi

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007. © 2020 Hellenic Society of Cardiolog

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and 651 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and 64 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores 642. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007